Outcomes of category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 11, 2012, Pages 1505-1509

  Sharma, S K ^a   Solanki, R ^b   Mohan, A ^c   Jain, N K ^d   Chauhan, L S ^e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Pulmonary Medicine   (India)

^c SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

^d SMS MEDICAL COLLEGE   (India)

^e GOVERNMENT OF INDIA   (India)

Author keywords

Category III; DOTS; Pleural effusion; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLEURA BIOPSY; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM SMEAR; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOUS PLEURISY; WEAKNESS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPETENCE; INDIA; ISONIAZID; MALE; PLEURAL EFFUSION; PROSPECTIVE STUDIES; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84867209649     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0233     Document Type: Article

References (16)

1. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003/13. Geneva, Switzerland: WHO, 2003.
2. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/2009. 420. Geneva, Switzerland: WHO, 2009.
3. Gopi A, Madhavan S M, Sharma S K, Sahn S A. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131: 880-889. (Pubitemid 46446885)
4. Karmakar S, Sharma S K, Vashishtha R, et al. Clinical characteristics of tuberculosis-associated immune reconstitution infl ammatory syndrome in North Indian population of HIV/ AIDS patients receiving HAART. Clin Dev Immunol 2011; 2011: 239021.
5. Ministry of Health and Family Welfare. Technical and operational guidelines for tuberculosis control. New Delhi, India: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2005.
6. Balik M, Plasil P, Waldauf P, et al. Ultrasound estimation of volume of pleural fl uid in mechanically ventilated patients. Intensive Care Med 2006; 32: 318-321. (Pubitemid 43251157)
7. Chauhan L S, Agarwal S P. The Revised National Tuberculosis Control Programme. In: Agarwal S P, Chauhan L S, eds. Tuberculosis control in India. New Delhi, India: Elsevier, 2005: pp 23-34.
8. Dixit R, Shelat G V, Gami S, Sharma S, Jindal S. Effi cacy of Category III treatment regimen for tuberculous cervical lymphadenopathy in Indian Revised National Tuberculosis Control Programme (RNTCP). Chest 2007; 132: 641-642.
9. Jain N K, Bajpai A, Jain S. Outcomes of Category III and I in immunocompetent patients of tuberculous lymphadenopathy treated in Revised National Tuberculosis Control Programme. Lung India 2010; 27: 115-117.
10. Ministry of Health and Family Welfare. TB India 2011. Revised National Tuberculosis Control Programme. Annual status report. New Delhi, India: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2011.
11. Barbas C S, Cukier A, de Varvalho C R, Barbas Filho J V, Light R W. The relationship between pleural fl uid fi ndings and the development of pleural thickening in patients with pleural tuberculosis. Chest 1991; 100: 1264-1267.
12. Han D H, Song J W, Chung H S, Lee J H. Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication. Chest 2005; 128: 3240-3245.
13. Lee C H, Wang W J, Lan R S, Tsai Y H, Chiang Y C. Corticosteroids in the treatment of tuberculous pleurisy. A doubleblind, placebo-controlled, randomized study. Chest 1988; 94: 1256-1259.
14. Kwon J S, Cha S I, Jeon K N, et al. Factors infl uencing residual pleural opacity in tuberculous pleural effusion. J Korean Med Sci 2008; 23: 616-620.
15. Paramasivan C N, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res 2004; 120: 377-386. (Pubitemid 39504473)
16. Jain A, Mondal R, Prasad R, Singh K, Ahuja R C. Prevalence of multidrug-resistant Mycobacterium tuberculosis in Lucknow, Uttar Pradesh. Indian J Med Res 2008; 128: 300-306.